Edward Via College of Osteopathic Medicine, Biomedical Sciences, Blacksburg, VA, USA.
Virginia Tech, Blacksburg, VA, USA.
Sci Rep. 2023 Aug 12;13(1):13131. doi: 10.1038/s41598-023-40256-9.
A hallmark of cancer is a tumor cell's ability to evade immune destruction. Somatic mutations in tumor cells that prevent immune destruction have been extensively studied. However, somatic mutations in tumor infiltrating immune (TII) cells, to our knowledge, have not been previously studied. Understandably so since normal hematopoiesis prevents the accumulation of somatic mutations in immune cells. However, clonal hematopoiesis does result in the accumulation of somatic mutations in immune cells. These mutations cannot "drive" tumor growth, however, they may "facilitate" it by inhibiting an effective anti-tumor immune response. To identify potential immunosuppressive clonal hematopoietic (CH) mutations in TII cells, we analyzed exome and RNA sequencing data from matched tumor and normal blood samples, and single-cell RNA sequencing data, from breast cancer patients. We selected mutations that were somatic, present in TII cells, clonally expanded, potentially pathogenic, expressed in TII cells, unlikely to be a passenger mutation, and in immune response associated genes. We identified eight potential immunosuppressive CH mutations in TII cells. This work is a first step towards determining if immunosuppressive CH mutations in TII cells can affect the progression of solid tumors. Subsequent experimental confirmation could represent a new paradigm in the etiology of cancer.
癌症的一个标志是肿瘤细胞逃避免疫破坏的能力。已经广泛研究了防止免疫破坏的肿瘤细胞中的体细胞突变。然而,据我们所知,肿瘤浸润免疫(TII)细胞中的体细胞突变以前尚未研究过。这是可以理解的,因为正常造血会阻止免疫细胞中体细胞突变的积累。然而,克隆性造血确实会导致免疫细胞中体细胞突变的积累。这些突变不能“驱动”肿瘤生长,但它们可能通过抑制有效的抗肿瘤免疫反应来“促进”它。为了鉴定 TII 细胞中潜在的免疫抑制性克隆性造血(CH)突变,我们分析了来自乳腺癌患者匹配的肿瘤和正常血液样本的外显子组和 RNA 测序数据,以及单细胞 RNA 测序数据。我们选择了那些在 TII 细胞中存在、克隆扩增、具有潜在致病性、在 TII 细胞中表达、不太可能是乘客突变、与免疫反应相关基因相关的体细胞突变。我们在 TII 细胞中鉴定出了八个潜在的免疫抑制性 CH 突变。这项工作是确定 TII 细胞中的免疫抑制性 CH 突变是否会影响实体瘤进展的第一步。随后的实验验证可能代表癌症病因学的一个新范例。